The emrAB locus of Escherichia coli encodes a multidrug resistance pump that protects the cell from several chemically unrelated antimicrobial agents, e.g., the protonophores carbonyl cyanide m-chlorophenylhydrazone (CCCP) and tetrachlorosalicyl anilide and the antibiotics nalidixic acid and thiolactomycin. The mprA gene is located immediately upstream of this locus and was shown to be a repressor of microcin biosynthesis (I. del Castillo, J. M. Gomez, and F. Moreno, J. Bacteriol. 173:3924-3929, 1991). There is a putative transcriptional terminator sequence between the mprA and emrA genes. To locate the emr promoter, single-copy lacZ operon fusions containing different regions of the emr locus were made. Only fusions containing the mprA promoter region were expressed. mprA is thus the first gene of the operon, and we propose that it be renamed emrR. Overproduction of the EmrR protein (with a multicopy vector containing the cloned emrR gene) suppressed transcription of the emr locus. A mutation in the emrR gene led to overexpression of the EmrAB pump and increased resistance to antimicrobial agents. CCCP, nalidixic acid, and a number of other structurally unrelated chemicals induced expression of the emr genes, and the induction required EmrR. We conclude that emrRAB genes constitute an operon and that EmrR serves as a negative regulator of this operon. Some of the chemicals that induce the pump serve as its substrates, suggesting that their extrusion is the natural function of the pump.
It has become clear in recent years that bacteria possess pumps of low specificity that can extrude structurally unrelated amphipathic toxins. These have been termed multidrug resistance pumps (MDRs). The MDRs are widely distributed, and their presence in pathogens such as Staphylococcus aureus (9, 10, 15, 16) and Pseudomonas aeruginosa (31) poses a serious threat to public health.
Three families of bacterial MDRs are known (13, 27) . The simplest one is the Smr (staphylococcal multidrug resistance) family of four membrane domain proteins which are by far the smallest known translocases of any kind. Discovered originally in S. aureus, Smr-encoding genes are carried on broad-hostrange plasmids (29) and are found in many bacteria including Escherichia coli (9, 10, 15, 16) . The Smrs extrude membranepermeable cations such as ethidium bromide and tetraphenylphosphonium. Another family is made up of the Acr (acridine) pumps that were originally thought to be components of the outer membrane. The Acr pumps are in the same family with the metal efflux translocases of Alcaligenes spp. and have the broadest substrate spectrum, protecting from sodium dodecyl sulfate, acriflavine, and a number of antibiotics such as novobiocin and rifampin (20, 31, 38) . The third family of MDRs constitutes the large major facilitator family (6, 22) and includes the QacA pump of S. aureus involved in the extrusion of quaternary ammonium compounds used as antiseptics (34, 36) and the Bacillus multidrug resistance (Bmr) pump extruding, among other compounds, ethidium bromide, puromycin, and chloramphenicol (26) ; this family also includes the wellstudied tetracycline/H ϩ antiporter (12) . The EmrAB pump of E. coli was found in an effort to identify the genetic basis of E. coli adaptation to protonophores which uncouple oxidative phosphorylation (18) . It was shown that emrAB expression conferred resistance to such structurally unrelated compounds as protonophores (carbonyl cyanide m-chlorophenylhydrazone [CCCP] and tetrachlorosalicylanilide [TCS]), 2-chlorophenylhydrazine, and some antibiotics (nalidixic acid and thiolactomycin). EmrAB consists of a translocase proper, the EmrB protein which is a member of the major facilitator family, and the EmrA protein, belonging to the membrane fusion family, that might have the function of organizing an efflux pathway for EmrB substrates across both the inner and the outer membranes (6, 18) . The addition of CCCP to E. coli growing under conditions of oxidative phosphorylation causes a marked decrease in growth rate, but the growth recovers within 1 to 2 h (25). This suggested that expression of emrAB can be induced by CCCP. We report here that the emrAB transcription initiates from the regulatory region of a previously described gene, mprA (4) , that the expression of emrAB can be induced by several structurally unrelated compounds, and that mprA encodes a repressor of the pump synthesis. Some of the chemicals that induce this operon serve as substrates for the pump. Because mprA is part of the emrAB operon, we propose that it be renamed emrR.
An additional promoter for the emrB gene is located in the emrA coding sequence. This promoter is independent of EmrR and will be the subject of another communication.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth media. The E. coli strains used in this study are listed in Table 1 ; plasmids are schematically shown in Fig. 1 and 3 . Luria-Bertani (LB) medium was used throughout. MacConkey agar supplemented with 1% lactose was used for screening the lacZ fusions. When necessary, ampicillin, tetracycline, or kanamycin (Sigma, St. Louis, Mo.) was added at a concentration of 100, 15, or 50 g/ml, respectively. Generalized transductions with P1vir were performed as described by Miller (24) . ␤-Galactosidase assays were performed with chlorophenol red-␤-D-galactopyranoside (CPRG) as described previously (19) . CPRG provides an approximately 10-fold-higher sensitivity than does o-nitrophenyl-␤-D-galactopyranoside (ONPG). The activity was calculated by Miller's formula but with CPRG optical density measurements and is expressed in arbitrary units (24) .
Molecular biology techniques. Chromosomal DNA for the PCR amplification was isolated as described by Liu and Turnbough (17) . Total cellular RNA for primer extension and plasmid DNA were isolated with the RNeasy total RNA kit or mini-or midiplasmid kits (Qiagen Inc., Chatsworth, Calif.). Restriction endonuclease digestion and ligation were carried out according to the manufacturer's protocols (New England Biolabs, Beverly, Mass.). Plasmids were introduced into bacteria by electroporation (21) . Restriction fragments were purified from agarose gels with a Geneclean II kit, purchased from Bio 101, La Jolla, Calif. Dideoxy sequencing was performed with the Sequenase version 2.0 DNA sequencing kit (United States Biochemicals, Cleveland, Ohio). A GeneAmp kit from Perkin-Elmer Cetus was used for PCR amplification of DNA.
Primer extension experiments were performed as previously described (21) . RNA was isolated either from overnight cultures or from log-phase cultures grown in LB medium. Primer 5Ј TGATAAGGAAAATCTTCGTGGCGGCTG complementary to 148 to 171 of the emrR sequence (numeration is by the method of Moreno and coworkers [5] ) was used to localize the promoter upstream of emrR. This and other primers were purchased from Operon Technologies, Inc. (Alameda, Calif.) or from Ana-Gen Technologies, Inc. (Sunnyvale, Calif.).
Construction of emr-lacZ single-copy fusion strains. Single-copy emr-lacZ operon fusions were generated with the system of Simons et al. (35) . The region of interest was first cloned upstream of the promoterless lacZ gene in multicopy plasmid pRS415. If the resulting plasmid produced a higher level of ␤-galactosidase activity compared with that of pRS415 itself, it was recombined into phage RS45, which was used to lysogenize AMS6 to yield a fusion strain. PCR was used to generate DNA fragments of various lengths. Primers were flanked by the appropriate restriction sites (EcoRI and BamHI) to permit directional cloning. The forward primers were as follows (see Fig. 1 ): MLM23, (ϩ603) GCGGAAT TCGGCAAGCAGGTCGGCTCA; MLM03, (ϩ456) GCGGAATTCCGAG CAAATCACCCGCAA; MLM43, (ϩ308) GCGGAATTCGTCGTGAAAGC GATAACG; MLM53, (ϩ81) GCGGAATTCTTCTGACTCGTCTTTGCA; and MLM63, (Ϫ155) GCGGAATTCCATCCCAACACTGCTTAG. The numbers in parentheses are the positions relative to the translational start site of emrR. Reverse primer GCGGGATCCGTGAGAAGGAGGAGCAGA was complementary to bases 66 to 83 downstream of the translational start site of emrA and was the same for the above-listed strains. The fusion MLM67 was obtained with the same forward primer as for the fusion MLM63 and with reverse primer CCCGGATCCCTGGATTTTTGAGCGAGA, complementary to bases 8 to 25 downstream of the TAA stop codon of emrR. To construct the MLB69 fusion, the following two primers were used: the forward (EcoRI) primer was the same as for construction of the MLM63 fusion; the reverse (BamHI) primer, GGGG GATCCGTGTTATCGGCCCAGACTTT, was complementary to bases 48 to 65 downstream of the emrB translational start site. The fusions MLM634 and MLB694 were obtained by deleting the SphI-XhoI fragment from the pMLM63 and MLB69 plasmids, respectively. The resulting fusions are thus deleted of emrR. To construct the MLB29 fusion, we used the same forward primer as for MLM23 and the same reverse primer as for MLB69.
Construction of pemrR and pemrR* plasmids. The emrR gene was amplified from the chromosome of E. coli AMS6 by PCR and cloned into the EcoRIBamHI-digested plasmid pGEM3Z to yield plasmid pemrR. Primers used for this PCR amplification were the same as for construction of the MLM63 fusion. These primers were also used to amplify mprA (emrR) from the chromosome of the Tlm r strain CDM5 (11) . The PCR product was cloned into the EcoRIBamHI-digested plasmid pUC18 to yield pemrR*.
Construction of the emrR, emrA, and emrB null mutants. The null mutants were constructed by the method of Winans et al. (37) , replacing the wild-type emr genes by emr genes inactivated by insertion of a kanamycin resistance gene. For emrR inactivation, the insertion was into the unique XhoI site of the plasmid pemrR; for that of the genes emrA and emrB, the insertions were into the NruI or PstI site, respectively, of the plasmid pemr 2.1 (18) . The source of the kanamycin cassette was plasmid pUC4K (Pharmacia). Disruption and loss of function were confirmed as follows: for emrR, by the inability of the plasmid bearing the disrupted gene to inhibit ␤-galactosidase activity of the emr-lacZ fusions (see Results), and for emrA and emrB, by the inability of the appropriate plasmids to confer CCCP resistance. The plasmids were digested with EcoRI and BamHI, and the appropriate fragment was eluted from the agarose gel and used to transform the strain JC7623. Kanamycin-resistant transformants were selected and tested for sensitivity to ampicillin. DNA from several Km r Ap s colonies was isolated and tested for gene disruption by PCR. P1 transduction was used to transfer emr::Km insertions into the appropriate genetic backgrounds.
Nucleotide sequence accession number. The nucleotide sequence data reported in this paper have been entered in the NCBI database under accession number U19993.
RESULTS
The genes for the multidrug resistance pump EmrAB form an operon with the upstream gene emrR. To identify the promoter of the emrAB locus, different-length fragments upstream of the emrA gene were cloned in the transcriptional fusion vector pRS415. The productive fusions were integrated into phage which were used to lysogenize E. coli AMS6 so as to study regulation in single-copy fusions.
A putative transcriptional terminator is present at nucleotide ϩ602 in relation to the emrR translational start site (5), i.e., between the emrR and emrA genes (Fig. 1) . We therefore expected to find a promoter in the 56-nucleotide-long DNA segment between these genes. However, a strain with plasmid pMLM23 containing the fusion to this segment had the same basal level of ␤-galactosidase activity as the pRS415-containing strain. This indicated the absence of a promoter immediately upstream of emrA. To test the possibility that the promoter was present in the coding region of the upstream emrR gene, fusions containing different lengths of this region were tested. However, even fusion pMLM53, which contains almost the entire coding region of emrR, was not productive (Fig. 1) .
The results suggested that emrA was transcribed from the emrR promoter. Testing this hypothesis required construction of fusions containing the emrR regulatory region. Since only a short fragment (98 bp) of this sequence was known, a 250-bp portion of this region was sequenced in order to design a primer for PCR amplification of a longer upstream segment. This enabled us to construct the plasmid pMLM63, which contains 155 bp upstream of the emrR translational start site fused to the lacZ gene (Fig. 1) . There was significant expression of ␤-galactosidase activity in this fusion, indicating that the emrA gene requires the emrR promoter for expression. For convenience, we will refer to this promoter as Pemr. Strain MLM63 was constructed by incorporating the fusion from pMLM63 in E. coli AMS6 through lysogenization and was used to study emrRA-lacZ expression in single-copy fusions.
The transcriptional start site of the emrRAB operon was determined by primer extension analysis. One major extension product corresponding to 23 bp upstream of the ATG start codon of the emrR gene was found (Fig. 2) . The Ϫ10 and Ϫ35 regions of Pemr possess a typical 70 promoter sequence; emrR is thus the first gene of the operon encoding the multidrug resistance pump EmrAB.
The emr operon contains an internal terminator. We sought direct evidence for the functionality of the putative terminator sequence downstream of emrR. Thus, we compared the ␤-galactosidase activity of emr-lacZ fusions in which the lacZ gene was fused either upstream (strain MLM67) or downstream (strain MLM63) of the terminator sequence. MLM67 showed a two-to threefold-higher activity than did MLM63 ( Table 2 ), indicating that the terminator sequence is functional, albeit weakly functional.
The emrR gene product is a negative regulator of the multidrug resistance pump. The emrR (mprA) gene was originally cloned as a multicopy suppressor of microcin B and C production (4). Overexpression of mprA (emrR) decreased transcription of the microcin B-encoding gene, mcb, as determined with an mcbA-lacZ fusion, while mprA deletion caused increased transcription (5) . The same study suggested that the mprA (emrR) gene is autoregulated, since mprA-lacZ expression was decreased in the presence of a multicopy plasmid bearing the mprA gene.
EmrR could regulate the EmrAB pump in a similar manner, and we therefore investigated the effect of emrR overexpression and inactivation on emr gene expression. A multicopy plasmid carrying emrR (pemrR) was introduced into strain MLM63 (emrRA-lacZ); ␤-galactosidase activity was decreased eightfold by the presence of this plasmid ( Table 2 ). The MLM63 strain contains two copies of the emrR gene, one in the chromosomal emr locus and the other on the emrRA-lacZ fusion. Inactivation of either copy produced a 7-to 8 ]). Introduction of the pemrR plasmid resulted in strong inhibition of expression. The amount of the primer extension product, which reflected the amount of Pemr-dependent transcript, was markedly increased when RNA isolated from emrR-lacking strain AMS6 emrR::Km was used as the template for the extension reaction (Fig. 2B) . These results indicate that emrR acts as a repressor of the emr locus.
The emrB gene has an additional promoter. emrA and emrB, being part of the same operon, should ordinarily be affected to the same degree by EmrR. In an emrRAB-lacZ fusion (MLB69 [ Fig. 3 Table 2 ]), showing that EmrR indeed had a strong effect on the last gene of the operon. At the same time, the basal level of ␤-galactosidase production of an emrRABlacZ fusion (strain MLB69) was higher than that of an emrRAlacZ fusion (MLM63 [ Fig. 1]) . Further, EmrR overexpression caused a less pronounced effect on emrRAB-lacZ compared with the emrRA-lacZ fusion. This suggested regulation of emrB by an additional promoter. Indeed, a fusion (MLB29) containing an upstream fragment of emrB, but lacking the Pemr promoter, was productive (Fig. 3) , confirming the presence of the additional promoter. As expected, this emrB-lacZ fusion was not affected by EmrR (Table 2) . This promoter will be the subject of a future communication.
The emrRAB operon can be induced by structurally unrelated drugs. When CCCP, TCS, or nalidixic acid was added to the exponentially growing culture of the MLM63 fusion strain, ␤-galactosidase activity increased 1.5-to 3-fold, indicating induction of Pemr (Fig. 4) . Maximal induction occurred at concentrations that inhibited cell growth. However, induction does not appear to result from such growth inhibition, since thiolactomycin inhibited growth but yet had no effect on induction.
Salicylate and other weak acids as well as 2,4-dinitrophenol have been shown to induce multiple antibiotic resistance in E. coli that is controlled primarily by the marRAB operon (3). Interestingly, EmrR is homologous to MarR, and we therefore tested whether salicylate and 2,4-dinitrophenol would also induce expression of the emr locus. These compounds induced (at the same concentrations at which they induce multiple antibiotic resistance) the MLM63 fusion strain by six-to eightfold (Fig. 4) . As expected from these results, the amount of the Pemr-dependent transcript also increased after salicylate addition ( Fig. 2A) . Many of the drugs mentioned above are weak acids. However, ethidium bromide, which is an amphiphilic cation, also induced the fusion in strain MLM63 (Fig. 4) , showing that truly unrelated substances can be inducers. Induction of Pemr activity by all inducers was abolished in strain OLS101, which does not have the emrR gene, while emrA or emrB mutations had no effect (data not shown). This indicates that the inducers act through emrR to activate transcription. It is noteworthy in this connection that overexpression of MarR or MarA, or mutations in the cognate genes, did not affect emr expression (data not shown).
In the multidrug resistance phenomenon, exposure to one chemical or drug often results in the development of resistance to unrelated drugs. This was true also of the EmrAB pump. Thus, cells of the AMS6 strain grown in the presence of 2.5 mM salicylate exhibited increased CCCP resistance compared with that in the unexposed control cultures; the adapted cells possessed a more than threefold-higher growth rate in the presence of CCCP compared with that of the unadapted cells (Fig. 5) .
EmrR and the nature of the thiolactomycin resistance mutation. An interesting mutation conferring resistance to the antibiotic thiolactomycin (Tlm r ) has recently been described and mapped to the emr locus (7). This mutation also increased resistance to CCCP (data not shown), as well as to the quantity of Pemr-dependent transcript (Fig. 2C) . The increase in the amount of the message could either be due to a promoter mutation or due to a mutation in the repressor. To distinguish between these possibilities, a complementation with the wildtype emrR locus was performed. The plasmid pemrR complemented the Tlm r mutation in strain CDM5 and conferred hypersensitivity to CCCP (Fig. 6) . Thus, the mutation is likely to be in the structural portion of the emrR gene.
To localize the Tlm r mutation, this locus was cloned from strain CDM5 into plasmid pUC18, yielding the plasmid pemrR*. The entire sequence of the emrR* gene from the plasmid pemrR* was determined and compared with the sequence of the wild-type emrR gene (Fig. 7) . A single mutation, insertion of an additional C at position 479 (relative to emrR translational start site), was found in the structural region; this was confirmed by direct sequencing of the PCR product. The mutation produces a frameshift starting from amino acid residue 160 of the EmrR protein. The frameshift creates a 36-amino-acid-long extension of the open reading frame (Fig. 7) .
Since no other change in the regulatory or structural part of the emrR gene was found, we conclude that this single frameshift mutation is the cause of multiple drug resistance of strain CDM5.
DISCUSSION
Our original analysis indicated that emrA and emrB genes make up a two-gene operon. The mprA (emrR) gene that is adjacent to emrA has a typical putative rho-independent terminator and was ascribed the function of regulating expression of microcin synthesis (4) . The use of lacZ fusions to systematically search for the promoter of the operon led to the unexpected finding that emrR was actually a part of the emrAB operon. Cloned portions of the emrA gene containing the DNA between the putative transcriptional terminator and the emrA translational start did not give productive fusions when linked to a promoterless lacZ gene, indicating the absence of a promoter in this region. However, when the upstream region was extended to include the emrR gene and its putative promoter region, a productive lacZ fusion resulted. Primer extension analysis confirmed that the transcriptional start site of emrA is indeed upstream of the emrR gene. As discussed in the introduction, we have therefore renamed mprA as emrR. The terminator downstream of emrR appeared to be functional, inhibiting transcription of the downstream genes two-to threefold. This mild inhibition suggests that an antiterminator mechanism is involved.
An additional promoter for the emrB gene was discovered. This promoter is located in the structural part of the emrA gene. Expression from this promoter is specifically increased when E. coli enters the stationary phase (19a) . The function of this additional promoter remains to be explored.
Our data further show that the EmrR protein acts as a negative regulator of the MDR pump. Placing emrR on a multicopy plasmid strongly inhibited the expression of a chromosomal emr-lacZ fusion, and conversely, an emrR null mutation caused a 40-fold increase in the activity of the fusion. The amount of emr message produced paralleled the results of fusion expression experiments. Overexpression of emrR increased the sensitivity of cells to CCCP, while a mutation in the repressor increased resistance to CCCP and the antibiotic thiolactomycin. Having the pump genes and the negative repressor of these genes as part of the same operon probably ensures a rapid and strong remedial response by the cell to exposure to deleterious drugs.
EmrR is homologous to a family of regulatory proteins. These proteins include a 17-kDa protein of unknown function (36% homology and 62% similarity) that is the product of the last gene of the prs operon which is necessary for expression of adhesion pili in uropathogenic E. coli (23) ; PecS, controlling pectinase, cellulase, and blue pigment production in Erwinia chrysanthemi (32) ; SlyA, which is involved in the production of salmolysin (14) ; MarR, a repressor of the E. coli mar locus conferring multiple antibiotic resistance (2, 8) ; HpcR, which regulates an inducible chromosomal gene cluster in E. coli that encodes homoprotocatechuate-degrading activity (33) ; and Hpr, which is involved in the regulation of protease production in B. subtilis (30) . None of these proteins, like EmrR, has known DNA-binding motifs (28) . We are now investigating whether the transcription repression caused by EmrR is due to direct binding to the promoter region. Sequence similarity has recently been found upstream of the promoter regions of Pemr and Pmcb (24a), strengthening the possibility that EmrR could directly bind to these promoters.
The EmrR repressor may serve as a relay mechanism for the signal(s) that controls the pump. Multiple drugs may directly bind to EmrR and induce MDR expression, a possibility now under investigation. It is noteworthy in this connection that a transcriptional activator of the Bmr multidrug resistance pump from B. subtilis has recently been found to directly bind a number of hydrophobic cations (that are substrates of the pump), which in turn leads to its interaction with the regulatory region of the bmr gene (1). The Bmr pump belongs to the same major facilitator family as EmrB, but BmrR is unrelated to EmrR, being a member of the Mer (mercury resistance) group of transcriptional activators. The fact that several structurally unrelated chemicals act as inducers as well as substrates for the EmrAB pump suggests that the physiological role of the translocase is indeed the extrusion of multiple drugs.
